Great Lakes Advisors LLC Takes $757,000 Position in Mirum Pharmaceuticals, Inc. $MIRM

Posted by on Aug 23rd, 2026

Great Lakes Advisors LLC bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,465 shares of the company’s stock, valued at approximately $757,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cullen Frost Bankers Inc. acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. bought a new stake in Mirum Pharmaceuticals in the 4th quarter valued at $32,000. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $32,000. State of Wyoming acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter valued at $52,000. Finally, Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth about $33,000.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $96.31 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $6.25 billion, a price-to-earnings ratio of -6.62 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 1-year low of $63.23 and a 1-year high of $130.00. The firm’s 50-day moving average price is $111.20 and its two-hundred day moving average price is $101.94.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The firm had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business’s revenue was up 37.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.12) EPS. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the senior vice president directly owned 1,274 shares of the company’s stock, valued at $127,400. This trade represents a 96.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were sold at an average price of $98.92, for a total value of $1,978,400.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $19,221,046.28. The trade was a 9.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 133,156 shares of company stock worth $13,763,562 in the last three months. Insiders own 8.32% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MIRM. CLSA set a $146.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Royal Bank Of Canada dropped their price target on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. Stifel Nicolaus set a $136.00 price objective on Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, HC Wainwright decreased their price objective on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $137.33.

Read Our Latest Analysis on Mirum Pharmaceuticals

Mirum Pharmaceuticals Company Profile

(Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

Read More

Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report).

Institutional Ownership by Quarter for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.